Regular Article
Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast Formation

https://doi.org/10.1006/bbrc.2000.2314Get rights and content

Abstract

A novel cDNA encoding a secreted form of osteoclast differentiation factor/tumor necrosis factor-related activation-induced cytokine (sODF/TRANCE, GenBank Accession No. AB037599) was sequenced from 5′ RACE cDNA clones of squamous cell carcinoma cell lines, SCC-4 and T3M-1 Cl.2, of which parental malignant tissues had caused severe humoral hypercalcemia. The sODF/TRANCE cDNA was composed of unknown 5′ end sequence followed by the 100% identical sequence of the ODF/TRANCE extracellular domain-coding region. The longest open reading frame (ORF) of the novel cDNA completely matched the 3′ end of the ORF of the ODF/TRANCE cDNA encoding C-terminal amino acid residues (74–318) in the extracellular region. The corresponding protein that reacted with the antibody specific for the extracellular domain of ODF/TRANCE was detected in the culture media conditioned by the cancer cells. Furthermore, human promyeloblastic leukemia cells, HL60, differentiated into osteoclast-like cells (OCLs) when cultured in the media conditioned by SCC-4 and T3M-1 Cl.2 cells. The differentiation of HL60 cells into OCLs was inhibited by the anti-ODF/TRANCE antibody. These results strongly suggest that sODF/TRANCE plays an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.

References (39)

  • D.L. Lacey et al.

    Cell

    (1998)
  • B.R. Wong et al.

    J. Biol. Chem.

    (1997)
  • M. Weissglas et al.

    J. Urol.

    (1995)
  • M. Nagai et al.

    Biochem. Biophys. Res. Commun.

    (1999)
  • C.A. O'Brien et al.

    J. Biol. Chem.

    (1999)
  • H. Yasuda et al.

    Bone

    (1999)
  • L. Lum et al.

    J. Biol. Chem.

    (1999)
  • P. Chomczynski et al.

    Anal. Biochem.

    (1987)
  • T. Suda et al.

    Methods Enzymol.

    (1997)
  • G. Harth et al.

    J. Biol. Chem.

    (1999)
  • N. Nakagawa et al.

    Biochem. Biophys. Res. Commun.

    (1998)
  • C.C. Pilbeam et al.

    Bone

    (1993)
  • L.C. Hofbauer et al.

    Bone

    (1999)
  • H. Yasuda et al.

    Proc. Natl. Acad. Sci. USA

    (1998)
  • D.M. Anderson et al.

    Nature

    (1997)
  • N. Takahashi et al.

    Endocrinology

    (1988)
  • T. Yoneda et al.

    Endocrinology

    (1991)
  • S. Honda et al.

    Japanese J. Cancer Res.

    (1988)
  • F. Lakhdir et al.

    Eur. J. Pediat.

    (1994)
  • Cited by (88)

    • Parathyroid hormone-related protein (PTHrP) and malignancy

      2022, Vitamins and Hormones
      Citation Excerpt :

      PTHrP is produced and released by a variety of tumors, including squamous cell carcinomas such as lung, head and neck, renal, bladder, ovarian and breast cancers. In addition to PTHrP, a number of other circulating proinflammatory cytokines (including EGF, GCSF, TNF-alpha, IL-1, IL-5, IL-6, IL-8 and IL-11) have been implicated in HHM to a more limited degree (Horwitz & Stewart, 2003; Nagai, Kyakumoto, & Sato, 2000). While HHM is typically a late finding in advanced metastatic disease associated with a poor and short-term prognosis (Bhandari et al., 2019), breast cancer patients experience a somewhat longer median survival of 3–4.5 months (de Wit & Cleton, 1994).

    • Association between single nucleotide polymorphisms of the estrogen receptor 1 and receptor activator of nuclear factor kappa B ligand genes andbone mineral density in postmenopausal Taiwanese

      2013, Taiwanese Journal of Obstetrics and Gynecology
      Citation Excerpt :

      It is possible that most of the participants were in the early postmenopausal stage in which trabecular bone (the main component of lumbar spine) loss was more prevalent [26]. The RANKL gene encodes two different mRNAs and thus two different proteins of 244 (variant 1) [27] and 317 (variant 2) [28] amino acids. Variant 2 has 73 more amino acids than variant 1 at the N-terminus.

    • RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer

      2013, American Journal of Pathology
      Citation Excerpt :

      We previously reported that RANKL synthesized by stromal cells plays an important role in osteoclastic bone resorption during oral cancer–associated bone destruction,7 as reported in cases of multiple myeloma,30 breast cancer,8–10 and prostate cancer.11,12 Production of RANKL by tumor cells has also been reported in multiple myeloma,17 breast cancer,9,14 renal cancer,16 prostate cancer,15 and oral cancers.18–20 Although these results suggest that RANKL produced by tumor cells is also involved in cancer-associated bone destruction, it has not been demonstrated that the RANKL produced by tumor cells actually participates in cancer-associated bone resorption.

    • Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss

      2013, Oral Oncology
      Citation Excerpt :

      Recent studies suggest OSCC cells are capable of regulating osteoclastogenesis as well as mature osteoclast function through numerous mechanisms, including RANKL/OPG signaling.22 In vitro studies have demonstrated in multiple myeloma as well as two oral squamous cell carcinoma cell lines, the ability of cancer cells to produce RANKL and induce osteoclastogenesis.23,24 As an essential factor for osteoclastogenesis, RANKL expression can be induced in stromal cells, including osteoblasts, by a variety of hormonal and cytokine stimuli including vitamin D3,25 IL-1β, IL-6, PTHrP, and IL-17.26

    View all citing articles on Scopus

    Abbreviations used: ODF, osteoclast differentiation factor; TRANCE, tumor necrosis factor-related activation-induced cytokine; sODF/TRANCE, soluble fragment of ODF/TRANCE; ORF, open reading frame; OCL(s), osteoclast like cell(s); TNF, tumor necrosis factor; OPGL, osteoprotegerin ligand; RANKL, receptor activator of NF-kB ligand; HHM, humoral hypercalcemia of malignancy; PTHrP, parathyroid hormone-related protein; FBS, fetal bovine serum; RACE, rapid amplification of cDNA ends; Ab, antibody; CT-R, calcitonin receptor; RANK, receptor activator of NF-κB; nt, nucleotide

    1

    To whom correspondence should be addressed. Fax: +81-19-654-4147. E-mail: [email protected].

    View full text